Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial

P Vermersch, A Czlonkowska… - Multiple Sclerosis …, 2014 - journals.sagepub.com
Background: In previous studies, teriflunomide significantly reduced the annualised relapse
rate (ARR) and disability progression. Objective: This phase 3, rater-blinded study …
被引用次数：400 相关文章

Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial

P Vermersch, A Czlonkowska… - Multiple Sclerosis …, 2014 - search.proquest.com
Objective: This phase 3, rater-blinded study (NCT00883337) compared teriflunomide with
interferon-beta-1a (IFN-1a). Methods: Patients with relapsing multiple sclerosis were …
[PDF] academia.edu

[PDF][PDF] Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial

P Vermersch, A Czlonkowska, LME Grimaldi… - 2013 - academia.edu
Background: In previous studies, teriflunomide significantly reduced the annualised relapse
rate (ARR) and disability progression. Objective: This phase 3, rater-blinded study …

Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial

P Vermersch, A Czlonkowska… - Multiple sclerosis …, 2014 - pubmed.ncbi.nlm.nih.gov
Background In previous studies, teriflunomide significantly reduced the annualised relapse
rate (ARR) and disability progression. Objective This phase 3, rater-blinded study …

Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial.

P Vermersch, A Czlonkowska… - Multiple Sclerosis …, 2014 - search.ebscohost.com
The article discusses the results of the phase 3, multicenter, rater-blinded study on patients
with relapsing multiple sclerosis (MS). It states that patients with MS were randomized to oral …

Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial

P Vermersch, A Czlonkowska, LME Grimaldi… - Multiple Sclerosis …, 2013 - sonar.ch
English Background: In previous studies, teriflunomide significantly reduced the annualised
relapse rate (ARR) and disability progression. Objective: This phase 3, rater-blinded study …

Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial.

P Vermersch, A Czlonkowska, LM Grimaldi… - Multiple Sclerosis …, 2013 - europepmc.org
Objective This phase 3, rater-blinded study (NCT00883337) compared teriflunomide with
interferon-beta-1a (IFNβ-1a). Methods Patients with relapsing multiple sclerosis were …

[引用][C] Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial.

P Vermersch, A Czlonkowska, L Grimaldi… - MULTIPLE …, 2014 - iris.unisr.it
Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple
sclerosis: a randomised, controlled phase 3 trial. IRIS IRIS Home Sfoglia Macrotipologie & …

[引用][C] Teriflunomide versus subcutaneous interferon beta-I a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial

P VERMERSCH, A CZLONKOWSKA… - Multiple …, 2014 - pascal-francis.inist.fr
Teriflunomide versus subcutaneous interferon beta- I a in patients with relapsing multiple
sclerosis: a randomised, controlled phase 3 trial CNRS Inist Pascal-Francis CNRS Pascal …
[PDF] researchgate.net

[PDF][PDF] Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial

P Vermersch, A Czlonkowska, LME Grimaldi… - 2013 - researchgate.net
Background: In previous studies, teriflunomide significantly reduced the annualised relapse
rate (ARR) and disability progression. Objective: This phase 3, rater-blinded study …